Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Hematology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CHIC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHIC2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. GST or His-tagged options for assay flexibility. |
View CHIC2 Products |
| Gene Delivery | CHIC2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to study vesicular trafficking and localization. |
View CHIC2 Products |
| Benchmark Ab | Anti-CHIC2 Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and ELISA development. |
View CHIC2 Products |
| Validator | CHIC2 siRNA Set For knockdown verification and target specificity assays. |
View CHIC2 Products |
| Related Target A | PDGFRA Crucial tyrosine kinase receptor; its fusion with FIP1L1 (via CHIC2 genomic deletion) drives clonal hypereosinophilic syndrome. |
View PDGFRA Products |
| Related Target B | FIP1L1 Fusion partner with PDGFRA resulting from the interstitial deletion of the CHIC2 locus on chromosome 4q12. |
View FIP1L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Membrane association and hydrophobic domain aggregation | Optimized solubilization tags and detergent-free buffer formulations ensuring conformational stability. |
| Subfamily off-target cross-reactivity (e.g., CHIC1) | Sequence-verified proteins with strict identity validation via Mass Spectrometry. |
| Lack of reliable positive controls | Recombinant benchmark antibodies with defined sequences and high-purity production. |
| False positives in knockdown validation | HPLC-purified siRNA pools targeting distinct exons of CHIC2 to ensure complete silencing. |
Live CHIC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic and diagnostic landscape surrounding CHIC2 is unique. Primarily recognized as a critical genomic marker, the deletion of the CHIC2 locus on chromosome 4q12 leads to the oncogenic FIP1L1-PDGFRA fusion gene, a primary driver of clonal hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL). While tyrosine kinase inhibitors (TKIs) like imatinib target the resulting fusion kinase, emerging research is focusing on CHIC2 itself as a vesicular membrane-associated protein involved in exosome regulation and intracellular trafficking.
The next wave of R&D is exploring the biological functions of intact CHIC2 in solid tumors and vesicular transport pathways. Investigating how CHIC2 modulation affects membrane dynamics and cellular signaling represents an emerging frontier in targeted oncology and hematology therapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Diagnostic / FISH Probes | Abbott Molecular, Cytocell | Hypereosinophilic Syndrome, AML | High-purity genomic and protein references for assay calibration. |
| Small Molecule Inhibitors | Novartis, Bristol Myers Squibb | FIP1L1-PDGFRA+ Leukemia | Screening assays utilizing PDGFRA and FIP1L1 recombinant proteins. |
| Targeted Gene Therapies / RNAi | Academic Research Institutes | Vesicular Trafficking Disorders | High-titer Lentivirus and validated siRNA for functional knockdown assays. |